Welcome to our dedicated page for Cresco Labs news (Ticker: CRLBF), a resource for investors and traders seeking the latest updates and insights on Cresco Labs stock.
Cresco Labs Inc. (CRLBF) generates a steady flow of news related to its cannabis cultivation, production, branded products and Sunnyside retail dispensaries. As a company that emphasizes a CPG approach to national cannabis brands and a customer-focused retail experience, its announcements often highlight new store openings, market entries and updates on financial performance.
Readers of this news feed can expect coverage of dispensary openings and expansions, such as new Sunnyside locations in regulated medical marijuana and adult-use markets. These stories typically describe how each store fits into Cresco Labs’ broader national footprint and its efforts to provide an educational, approachable retail environment for patients and consumers.
The company also issues financial and operating results updates, including quarterly earnings releases that outline revenue, gross profit, net income or loss and non-GAAP metrics like Adjusted EBITDA and Adjusted gross profit. These releases are often paired with information about conference calls and webcasts for investors, as well as references to related filings on SEDAR+ and EDGAR.
Another key category of Cresco Labs news involves capital structure and financing. The company has announced commitments and closings for senior secured term loan refinancings, describing how these transactions affect its debt profile, maturity schedule and financial flexibility.
Policy and regulatory developments also appear in the news flow. Cresco Labs has commented on significant changes in U.S. cannabis regulation, including federal rescheduling actions, and has framed these events in the context of its mission to normalize and professionalize the cannabis industry. For investors and observers, following CRLBF news provides insight into how the company is expanding its brand portfolio, managing its balance sheet and responding to evolving cannabis laws.
Cresco Labs (OTCQX: CRLBF) reported Q1 2026 revenue of $151 million, gross profit of $75 million and Adjusted gross profit of $77 million (Adjusted gross margin 50.7%). SG&A was $54 million (36.0% of revenue); Adjusted SG&A was $51 million (33.7%). Net loss was $17 million; Adjusted EBITDA was $33 million (Adjusted EBITDA margin 21.7%).
As of March 31, 2026, cash and equivalents were $67 million; senior secured term loan was $310 million and mortgage loan $19 million. Subsequent items include conditional Texas medical license award, nine PA dispensary management openings, and two Ohio dispensary openings.
Cresco Labs (OTCQX: CRLBF) opened Sunnyside Aberdeen in Aberdeen, Ohio on May 5, 2026. This is the company’s second Ohio dispensary opened within a month, bringing Cresco Labs to 8 locations in Ohio and 74 locations nationally. Store hours are 9 a.m.–9 p.m.; pickup available at www.sunnyside.shop.
Cresco Labs (OTCQX:CRLBF) will report first quarter 2026 financial results on Friday, May 8, 2026 before the market opens. The company will host an earnings conference call and webcast at 8:30 am ET. Archived webcast access will be available for one year on the investor relations website.
Cresco Labs (OTCQX: CRLBF) opened Sunnyside Bridgeport at 435 Main Street, Bridgeport, Ohio on April 10, 2026. It is Cresco Labs' seventh dispensary in Ohio and its 73rd across the U.S.
The store is open daily 9 a.m.–9 p.m., sells Cresco Labs brands including Cresco, Supply, Good News, Mindy’s and Wonder, and offers online ordering for pickup at www.sunnyside.shop.
Cresco Labs (OTCQX: CRLBF) announced on April 2, 2026 that it was conditionally awarded a Texas Compassionate Use Program license. The vertically integrated license permits Cresco Labs to cultivate, process and dispense medical cannabis in Texas.
The company said the award supports its state-by-state growth strategy, enables capital-efficient market entry through organic licensing, and secures access to Texas’s ~30 million residents as patient access evolves.
Cresco Labs (OTCQX: CRLBF) reported Q4 2025 revenue of $162 million and fiscal 2025 revenue of $656 million, with strengthened margins and cash generation. Adjusted EBITDA was $40 million in Q4 and $157 million for the year. Operating cash flow was $27 million in Q4 and $73 million for the year.
The company posted a FY net loss of $140 million and Q4 net loss of $89 million reflecting one-time, non-cash impairment charges. Cash and equivalents totaled $91 million and senior secured term loan debt was $311 million.
Cresco Labs (OTCQX: CRLBF) will report full year and fourth quarter 2025 financial results on Thursday, March 5, 2026 before the market opens. A conference call and webcast are scheduled at 8:30 am ET to discuss results and business highlights.
Archived webcast access will be available for one year on the investor relations website. Dial-in and registration details are provided for investors.
Cresco Labs (OTCQX: CRLBF) entered an equity distribution agreement with Haywood Securities to establish an at-the-market (ATM) program to sell up to ~US$100 million (C$140 million) of subordinate voting shares.
Proceeds are intended for general corporate purposes, including potential acquisitions; no shares have been sold to date. The program is offered under a prospectus supplement dated January 29, 2026, and sales will occur on Canadian marketplaces in compliance with applicable securities laws.
Cresco Labs (OTCQX: CRLBF) opened Sunnyside Tamarac at 6001 N University Drive in Tamarac, Florida, marking its 31st dispensary in Florida and 72nd location nationwide.
The store offers products from Cresco Labs' brand portfolio including Cresco, FloraCal, Supply, Good News, Remedi and Sunnyside, plus accessories; orders can be placed in store or online at www.sunnyside.shop. Store hours: Monday–Friday 9:00 a.m.–8:00 p.m.; Sunday 9:00 a.m.–6:00 p.m.
Cresco Labs (OTCQX: CRLBF) issued a CEO statement after President Trump rescheduled cannabis from Schedule I to Schedule III under the Controlled Substances Act on December 18, 2025. The company called the move a historic shift that enables expanded medical research, eases the industry's federal tax burden, and advances banking reform and U.S. capital market access. The statement cited public support figures and noted implications for the estimated 450,000 workers in the regulated cannabis industry.